ABSTRACT: Introduction: The long exercise test (LET) is used to assess the diagnosis of periodic paralysis (PP), but LET methodology and normal "cutoff" values vary. Methods: To determine optimal LET methodology and cutoffs, we reviewed LET data (abductor digiti minimi motor response amplitude, area) from 55 patients with PP (32 genetically definite) and 125 controls. Receiver operating characteristic curves were constructed, and area under the curve (AUC) was calculated to compare (1) peak-to-nadir versus baseline-to-nadir methodologies and (2) amplitude versus area decrements. Using bayesian principles, we calculated optimal cutoff decrements that achieved 95% posttest probability of PP for various pretest probabilities (PreTPs). Results: AUC was highest for peak-tonadir methodology and equal for amplitude and area decrements. For PreTP 50%, optimal decrement cutoffs (peak-tonadir) were > 40% (amplitude) or > 50% (area). Discussion: For confirmation of PP, our data endorse the diagnostic utility of peak-to-nadir LET methodology using 40% amplitude or 50% area decrement cutoffs for PreTP 50%.
The long exercise test (LET) is a neurophysiological technique used to help establish the diagnosis of PP and builds on the observation that attacks of weakness often occur during a period of rest following strenuous exercise. As originally described, the LET involves measuring the change in compound muscle action potential (CMAP) amplitude over time after a period of sustained isometric exercise of the recorded muscle. Most patients with PP exhibit a progressive and gradual decline in CMAP amplitude and area due to reduced muscle fiber excitability. However, the cutoff values for amplitude or area decrements that have been used to define an abnormal LET result, along with the method used to calculate these decrements, have varied in the literature (see Supp. Info. Table 1 ). Two different methods are those of (1) McManis and colleagues 3 (hereafter referred to as the peak-to-nadir method) who defined the LET amplitude decrement as a percentage of the highest postexercise (peak) value (i.e., [peak 2 nadir] / peak 3 100) versus those of Fournier and colleagues 4 (hereafter referred to as the baseline-tonadir method) who defined amplitude decrement as a percentage of the pre-exercise baseline value (i.e., [baseline 2 nadir] / baseline 3 100) rather than the postexercise peak. The cutoff for an abnormal LET amplitude decrement was >40% (peak-to-nadir) versus > 20% (>2 standard deviations above the control mean, baseline-to-nadir). Decrement in area has also been used with a cutoff of 47% when using the peak-to-nadir method for decrement calculation. 5 In most studies, abnormal cutoff values were defined as 2 standard deviations above the mean, as calculated from a cohort of healthy controls. Few studies employed receiver operator characteristic (ROC) curve analyses, which optimize sensitivity and specificity, to determine cutoff values, and none compared the diagnostic utility of different methods to each other. In addition, all prior Abbreviations: ADM, abductor digiti minimi; ATS, Andersen-Tawil syndrome; AUC, area under the curve; CC, combined control; CMAP, compound muscle action potential; DC, disease control; HOPP, hypokalemic periodic paralysis; GDPP, genetically definite periodic paralysis; HV, healthy volunteers; HYPP, hyperkalemic periodic paralysis; LET, long exercise test; PostTP, posttest probability; PP, periodic paralysis; PreTP, pretest probability; ROC, receiver operating characteristic; URMC, University of Rochester Medical Center Key words: Bayes' Theorem; long exercise test; neurophysiology; periodic paralysis; posttest probability; receiver operating characteristic curve; sensitivity; specificity Conflicts of Interest: R. C. G. has received personal compensation from PTC Therapeutics, Idera Pharmaceuticals, Sarepta, Marathon, Strongbridge, Taro Pharmaceuticals, and MedPace; has received royalties and research support from Marathon and PTC Pharmaceuticals; and serves as correspondence editor for Neurology. None of the other authors have any conflicts of interest to disclose.
Correspondence to: E. Logigian; e-mail: eric_logigian@urmc.rochester. edu studies of the LET dichotomize continuous variables (e.g., LET amplitude or area decrement) into "normal" and "abnormal" based on a single cutoff value, a practice that is associated with several practical problems. First, this simple categorization does not adequately reflect the degree of abnormality of the results because a highly abnormal result may be interpreted with more diagnostic confidence than a minimally abnormal result. Second, fixed cutoffs do not integrate pretest probability (PreTP) of disease as determined by the physician's clinical impression, which for a given test outcome has an important effect on posttest probability (PostTP) of disease, as predicted by Bayes' theorem.
The present study represents a large cohort of patients with genetically definite primary PP. Our objective was to compare the diagnostic performance of the LET for (1) peak-to-nadir versus baseline-to-nadir methodology and (2) amplitude versus area decrement using ROC curves. We then applied Bayes' theorem to calculate optimal cutoffs to achieve 95% PostTP of PP for a wide range of PreTPs, as our group has done in prior electrodiagnostic studies of carpal tunnel syndrome 6 and of ulnar neuropathy at the elbow. 7 
MATERIALS AND METHODS
Clinical Data Collection. This retrospective study was approved by the University of Rochester Medical Center (URMC) Institutional Review Board. A list of patients referred for evaluation of periodic paralysis was generated from the URMC EMG database. Clinical data from the electronic medical record system were compiled by the first author (D.B.S.), and electrodiagnostic data were compiled separately by the second author (J.L.). In addition, cases were obtained via personal communication from other authors (R.T., J.C.C., A.P.).
Patients were considered for inclusion in the periodic paralysis cohort according to the following criteria (adapted from Sansone et al. 8 ): (1) pathogenic mutations in the SCN4A or CACNA1S known to cause periodic paralysis (patient or first degree relative), (2) at least 2 attacks of flaccid quadriplegia, (3) documented ictal serum hypokalemia or hyperkalemia, (4) positive family history of periodic paralysis, and (5) at least 2 of the following: (a) typical attack triggers, (b) onset of symptoms prior to age 30 years, and (c) positive response to oral potassium (hypokalemic periodic paralysis [HOPP] only). Patients were considered "genetically definite" if they met criteria 1 and 2, "clinically definite" if they met criteria 2 and 5 plus either 3 or 4, and "clinically probable" if they met criteria 2 and 5 only. Data from the patients' LETs were not considered in the inclusion process.
Patients with suspected Andersen-Tawil syndrome (ATS) were included on the basis of the following criteria (adapted from Venance et al. 9 ): (1) genetic mutation of the KCNJ2 gene, (2) clinical history of periodic paralysis, (3) ventricular ectopy or prolonged QT interval, and at least 2 of the following physical features: (a) low set ears, (b) short stature, (c) hypognathia or micrognathia, (d) clinodactyly or syndactyly, and (e) hypotelorism or hypertelorism. Patients were considered genetically definite if they met criteria 1 and 2 and clinically definite if they met criteria 2 and either 3 or 4. Data from the patients' LETs were not considered in the inclusion process for the ATS subgroup.
A small number of questionable cases were flagged and reviewed by an author with clinical expertise (R.T.), who was blinded to the patients' LET results, to determine eligibility for inclusion. The remaining non-PP patients were considered for inclusion in the "disease control" (DC) group. The DC group consisted of patients who presented with periodic weakness but who were determined, after chart review, not to have a primary PP according to the predefined clinical criteria listed above (without consideration of LET results). A second control group consisting of healthy volunteers (HV) was recruited primarily from hospital or clinic staff members. No clinical data were collected from this cohort other than verbal confirmation of the absence of neuromuscular symptoms prior to testing. In this article, we focus on the genetically definite PP (GDPP) versus HV data as the "purest" comparison because the risk of false positives in the GDPP group and of false negatives in the HV group is exceedingly low.
Electrodiagnostic Data Collection. LETs were performed by a certified electromyography technologist or neurophysiology fellow in accordance with the protocol described by McManis 3 by using a 2-channel Nicolet VikingQuest EMG (Natus Medical, Inc., Pleasanton, CA) recording the abductor digiti minimi (ADM) by using 10-mm recording and reference surface electrodes with supramaximal percutaneous stimulation at the wrist. Temperature at the wrist was maintained between 32 8C and 36 8C. After 10 min of rest, the ADM CMAP amplitude and area were recorded every 30 s for 8 responses. The ADM was then exercised isometrically for a period of 5 min with 3 s of rest every 15 s. Responses were recorded every minute during exercise and every 2 min after exercise for 46 min. Amplitude and area increments were calculated with the equation (baseline 2 peak) / baseline. Amplitude and area decrements were calculated by the peak-to-nadir method ([peak intraexercise Statistical Analysis. Means and 99% confidence intervals were calculated for amplitude and area with respect to baseline, peak intraexercise or postexercise, nadir, time to nadir, increment, and decrement (calculated by using both peak-to-nadir and baseline-to-nadir methods). The nadir for CMAP amplitude and for area was defined as the lowest value over the 46-min postexercise time period. Because of unequal variances, Welch's t test was used to compare each control group independently to the PP group. P < 0.01 was considered statistically significant. ROC curves were generated for each comparison with 1-specificity on the x-axis and sensitivity on the y-axis. The Pythagorean theorem was used to identify optimal cutoffs for each ROC curve. The trapezoidal rule was used to calculate area under the curve (AUC).
Bayesian Analysis. PostTP was defined as (PreTP 3 sensitivity) / [(PreTP 3 sensitivity) 1 (1 2 PreTP) 3 (1 2 specificity)]. PreTP levels were defined arbitrarily as 10%, 25%, 50%, 75%, and 90%. For each level of PreTP, the corresponding PostTP was calculated over all possible decrements between 0 and 70%.
RESULTS
Patient Selection. The URMC EMG database search resulted in 190 patients evaluated between January 1999 and April 2017. After electronic record review, 43 patients were included in the primary PP cohort. An additional 12 cases were obtained from 3 of the authors' (R.T., J.C.C., A.P.) research files. Thus, the total primary PP cohort consisted of 55 individuals (mean age 30.2 years, 67% male), including 32 patients with GDPP consisting of 12 HOPP, 10 hyperkalemic periodic paralysis (HYPP), 8 ATS, 1 normokalemic PP, and 1 HYPP/paramyotonia congenita overlap. Characteristics of the PP group are listed in Supporting Information Table 2 . The remaining patients with available data who were excluded from the PP cohort on clinical grounds were considered for inclusion in the DC group and consisted of 82 patients with various neuromuscular (excluding other known muscle channelopathies) or nonneuromuscular conditions (mean age 35.8, 34% male). The HV group consisted of 43 participants (mean age 35.8, 21% male).
Electrodiagnostic Results. A summary of the electrodiagnostic values for the GDPP versus HV comparison are shown in Table  T1 1. Results for the PP versus DC and PP versus HV comparisons may be found in Supporting Information Table 3 . With an a level of 0.01, mean baseline, peak, and nadir CMAP amplitude and area of the GDPP group were significantly lower than those of the HV group. Mean GDPP amplitude and area decrements using both the peak-to-nadir and baselineto-nadir methods were significantly greater than HV. When the entire PP cohort (with and without genetic mutations) was compared with the HV group, these differences remained significant (Supp. Info. Table 3 ). Mean time to nadir was 29.7 min in GDPP and 32.7 min HV (P 5 0.32). GDPP amplitude and area increment was not statistically different from the HV group. Comparison of HV and DC control groups revealed statistically lower mean CMAP amplitude and area in the DC group at all time points, whereas there were no differences in percentage decrement by any methodology. Comparisons of electrodiagnostic values between the HYPP and HOPP subgroups were not statistically different (data not shown). There were no sex differences in any group except for mean amplitude at nadir (5.6 mV for men vs. 8.0 mV for women, P 5 0.002) for the PP cohort.
ROC Curve Analyses. ROC curves were generated that compared both amplitude and area decrement cutoffs measured by both peak-to-nadir and baseline-to-nadir methods. These 4 ROC curves were constructed for (1) the GDPP subgroup versus the HV group, (2) the entire PP cohort versus the HV group, (3) the entire PP cohort versus the DC group, and (4) the entire PP cohort versus the combined control (CC) group. AUC was consistently higher with the peak-to-nadir method compared with the baseline-to-nadir method in all 16 ROC analyses (Table  T2 2), although the differences were generally small. The greatest AUC differences between the peak-to-nadir and baseline-to-nadir method curves was found in the GDPP versus HV comparison for both amplitude (AUC 0.84 vs. 0.78) and area (AUC 0.83 vs. 0.73) in favor of the peak-to-nadir method (Fig.  F1  1) . There was no consistent trend favoring the use of amplitude versus area decrement. Optimal cutoffs for the GDPP versus HV comparison were >34% for amplitude and >43% for area when measured by the peak-to-nadir method ( Table 2) . When the entire PP cohort was considered in the comparisons versus the HV and DC groups, optimal cutoffs were nearly identical.
Bayesian Analysis. The importance of PreTP and degree of decrement in predicting PostTP is most obvious below amplitude decrement of 40% or area decrement of 50% ( Fig.  F2 2); in this range, the same test result has a markedly different PostTP depending on PreTP, and, for the same PreTP, the PostTP of disease rises with amplitude decrement. For amplitude decrements above 40% and area decrements above 50%, specificity is essentially 100%, and, therefore, PostTP is above 95% for all preTPs.
With respect to the GDPP versus HV comparison, the amplitude and area cutoffs required to achieve a 95% PostTP for each level of PreTP are listed in Table  T3 3. In patients for whom the PreTP of disease is 50% or less, the required cutoffs were >40% for amplitude and >50% for area by the favored peak-to-nadir method. When the PreTP was 90% or higher, more liberal cutoffs could be applied. Comparisons involving the entire PP cohort with the HV group resulted in similar cutoffs, whereas the PP versus DC and the PP versus CC comparisons resulted in more conservative cutoffs (Supp. Info. Tables 4, 5, 6).
DISCUSSION
There is no consensus regarding the optimal cutoffs or methodology by which to measure LET decrements. Previous authors have published recommended cutoff values ranging from >28% to > 40.9% for amplitude decrement and from >40% to > 60% for area decrement.
3-5,10-12 The majority of these groups defined abnormal decrements as 2-3 standard deviations above the mean of control participants. Sample sizes ranged from 10 to 30 PP participants and from 15 to 65 controls. Assuming a bell-shaped curve, these cutoffs automatically result in highly specific tests but do not optimize sensitivity. Regarding methodology, 2 groups published separate cutoffs for amplitude and area, 5,10 and one 10 provided cutoffs for both peak-to-nadir and baseline-to-nadir methods; however, the statistical merits of these methods were not directly compared with each other.
In this context, our study provides comparative information on the various methods to calculate CMAP decrement and on choosing optimal decrement cutoffs. The use of ROC curves results in a more balanced diagnostic performance incorporating both specificity and sensitivity. Without regard to PreTP, our ROC curve analyses identified optimal cutoff values of >34% (amplitude) and >43% (area) as measured by the peak-to-nadir method. However, these cutoffs will fail to capture approximately 1 in 4 PP cases because the sensitivity is only 75%-79% and, more importantly, will misidentify approximately 1 in 5 non-PP cases as abnormal because the specificity for these ROCderived cutoffs is only 81%-84%.
By using a bayesian approach, the positive predictive value of the LET can be improved by incorporating the clinician's PreTP of PP. Bayesian analysis revealed that, when the PreTP is equivocal (50%) or less, more conservative cutoffs of >40% (amplitude) and >50% (area) are required to achieve a high degree of diagnostic certainty (i.e., PostTP 95%). This amplitude cutoff is identical, or nearly so, to that recommended by previous authors (McManis et al., 3 Kuntzer et al., 5 Tan et al. 10 ). Only when the PreTP is high (90%) can more liberal cutoffs of >25% (amplitude) and >36% (area) be applied. By contrast, the negative predictive value of the LET is not enhanced with a FIGURE 2. Posttest probability curves for varying levels of pretest probability. Amplitude (at left) and area (at right) decrements by the peak-to-nadir method for the genetically definite periodic paralysis versus healthy volunteer comparison. bayesian approach. This is because of the poor discrimination of false positives from true positives if the cutoff values are set too low (e.g., < 17% amplitude decrement for the peak-to-nadir method). This means that, for all decrement cutoffs, PostTP is always greater than or equal to (i.e., never less than) PreTP. Thus, even an LET decrement of 0% will not drop the posttest probability below the pretest probability (Fig. 2) . Therefore, a low decrement on the LET is not helpful in excluding PP. Just as we had anticipated, AUCs were highest for the purest GDPP versus HV comparison. With regard to specific LET methodology, our ROC data support the view that the peak-to-nadir method to calculate decrement consistently yields slightly higher AUCs for both measurements (CMAP amplitude and area) and for all group comparisons (GDPP vs. HV, PP vs. HV, PP vs. DC, PP vs. CC) compared with the baseline-to-nadir method. To illustrate this point further, there were 7 (13%) patients in the PP cohort with an abnormal amplitude decrement of >40% according to the peak-to-nadir method (i.e., cutoff required to achieve 95% PostTP when PreTP is 50%) who had normal amplitude decrements according to the baseline-to-nadir method. Five of these 7 patients were genetically definite. Conversely, only 1 (2%) patient in the PP cohort with a normal exercise test result according to the peak-to-nadir method had an abnormal amplitude decrement by the baseline-to-nadir method.
In addition, although the ROC curve data show no advantage of using decrement in CMAP area over amplitude for either method of calculation because AUC for amplitude and area were very similar in most comparisons, it is useful to calculate both amplitude and area decrements. For example, there were 6 patients in the entire PP cohort (5 with GDPP) with abnormal area decrements (>50%) according to the peak-to-nadir method who had normal amplitude decrements, and there were 3 patients with abnormal amplitude decrements (>40%) who had normal area decrements. Indeed, the combined sensitivity of an amplitude (>40%) or area (>50%) decrement in the entire PP cohort was 64% versus individual sensitivities of 53% for amplitude and 54% for area, whereas specificity in the HV group remained 100%. In a similar manner, in the GDPP cohort, the combined sensitivity of an amplitude (>40%) or area (>50%) decrement was 75% versus individual sensitivities of 59% for amplitude and 68% for area, whereas specificity in the HV group remained unchanged at 100% (Table  T4  4 ). When the PP and GDPP patient groups were compared with the DC group, the specificities were only slightly lower: 94% (amplitude only), 95% (area only), and 93% (amplitude or area).
Just as with prior studies, we emphasized the comparison of genetically definite PP patients versus HVs to contrast methodologies. In the ROC curve analyses, the use of HVs and symptomatic non-PP patients as separate control groups generally resulted in similar cutoffs. However, in the bayesian analysis, more conservative cutoffs were required to achieve high PostTP in the DC group compared with the HV group. The reason for this is unclear, but may be related to the inclusion of GDPP, genetically definite periodic paralysis; HV, healthy volunteer; PostTP, posttest probability PreTP, pretest probability. GDPP, genetically definite periodic paralysis; HV, healthy volunteer; LET, long exercise test; PostTP, posttest probability; PP, periodic paralysis; PreTP, pretest probability.
other neuromuscular disorders with secondary abnormalities of muscle membrane excitability in this group, although known channelopathies were excluded. There are 2 additional points to be addressed. First, PP and DC patients had lower mean amplitude and area at all time points in the LET (baseline, intraexercise/postexercise peak, nadir) compared with HV controls. This was not unexpected for the DC group, which consisted of patients with known neuromuscular diseases. It should be noted that the PP group had lower mean decrements than the DC group by all methodologies (Supp. Info. Table 3 ), whereas there were no differences in decrements between the DC and HV controls, a finding which we believe strengthens the generalizability of the LET to a neuromuscular population. The reason for reduced amplitude and area in the PP group is not known and warrants replication in other cohorts; however, we have reasoned that it may be indicative of subclinical, perhaps longstanding, muscle injury consistent with the finding of myopathic motor units by electromyography in some of our patients with PP. Second, a recently published article has suggested the requirement for different cutoff values for men and women. 13 Although we did find that men with PP had significantly lower CMAP amplitude (but not area) at nadir compared with women, there was no statistical difference for amplitude or area decrement. Therefore, because the LET relies on percentage change over time rather than absolute values at single time points, the cutoffs suggested by our data may be applied equally to patients of either sex. It is also notable that the PP group contained a higher proportion of men (approximately 2:1) than either control group in our study, in which the ratios were reversed. Again, in the context of essentially equal decrements between sexes, we do not think that this should limit the generalizability of the cutoffs. It also does not alter our conclusions regarding methodology (e.g., peak-to-nadir vs. baseline-to-nadir, amplitude vs. area methods) because the control groups are statistically similar for all measurements of decrement.
We used a standardized LET laboratory protocol in 55 patients (32 genetically definite) and 125 controls over a 20-year period. We built upon the work of previous groups by generating ROC curves for the comparison of peak-to-nadir and baselineto-nadir methods as well as for the comparison of area and amplitude decrements. We further incorporated pretest probability of disease by using Bayes' theorem to establish different cutoff values for varying levels of clinical suspicion for PP. Two other groups have recently published ROC analyses to establish optimal cutoff values. Ding et al.
14 used the baseline-to-nadir method, whereas Jin et al. 13 used the peak-to-nadir method, and both considered amplitude only. Only 1 of 103 patients from the combined cohort had positive genetic testing. It is noteworthy that the strict avoidance of allowing the LET to influence the clinical diagnosis to prevent incorporation bias was not specifically ensured in either study. We attempted to minimize the risk of this incorporation bias by separating the clinical from the electrophysiological data collection so that the investigator who determined inclusion into the PP or control groups was effectively blinded to the results of the LET.
This study has some limitations, the most important of which are related to assignment of patients into the PP and non-PP subgroups. Although we can be essentially certain that the GDPP patients had PP and that HV controls did not, we are less certain that some patients in the DC group may not have had PP because the published diagnostic inclusion criteria we used are designed for research purposes to maximize cohort purity. We recognize that our control groups had a lower percentage of men than did the PP groups, but we doubt that this affected our results and conclusions because there was no difference in amplitude or area decrement in men versus the women control patients. We also note that we currently have no quantitative method to determine PreTP of the diagnosis of periodic paralysis, but, as we have argued before, 6 we believe that neuromuscular clinicians can effectively provide a rough estimate of likelihood of disease (e.g., unlikely [25%], equivocal [50%], likely [75%]). We did not collect data on the timing of the most recent attack, 11 which may have influenced our data set. It is unlikely, in our opinion, that our cohort is different in this respect compared with prior studies. Finally, 2 statistical limitations should be addressed. First, our participants were chosen from a rare group of patients, many of whom were referred to our center specifically for evaluation of PP. As such, our results do not represent a random sample and may not be generalizable to the population at large. Second, although our sample size is large by rare disease standards and we incorporated all cases known to us which met prespecified clinical criteria, our methods did not account for sample size criteria determinations recommended for bayesian analyses of diagnostic tests in the absence of a gold standard. 15 This underscores our focus on the GDPP versus HV comparisons because a positive genetic test for PP in the setting of supportive clinical features ensures a very low rate of false positives in this cohort, and the rarity
